glp 1 drug market GLP-1 Receptor Agonist Size & Analysis, 2026-2033 Market share of GLP-1 RAs

S.de PaivaI

Lancet Diabetes Endocrinol 3(5):367381 van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, van Raalte DH (2017) SGLT2 inhibition in the diabetic kidneyfrom mechanisms to clinical outcome

prescriptions, a staggering jump reflecting how clinical results, not just marketing, drove adoption

Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial

[DOI] [PMC free article] [PubMed] [Google Scholar] 22.Reich N., Hlscher C

B.BuszaG.HolmesC.RitchieC.et al (2019)